NCT00156910 - A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches | Biotech Hunter

Enrollment

679

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

July 31, 2008

Conditions

Migraine Disorders

Interventions

BIOLOGICAL

Botulinum Toxin Type A

Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.

OTHER

Placebo (saline)

Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.

Trial Locations (2)

Unknown

Seattle

Markham